Replies to post #131365 on Biotech Values

[mcbio]

Look at RIGL's RA drug, they have been studied in more patients in phase 2 and currently in phase 3, should have results in next 6-8 months, RIGL's enterprise value currently at $230m. This should give you idea how market value other oral RA drugs at the moment.

Well, you know how I feel about RIGL (think they're relatively undervalued though I don't want to play those initial Phase 3 results, as we previously discussed). Also, I think a lot of RIGL's lower valuation as it pertains to their RA drug is due to some of the safety questions (which I think have a good chance to be put to rest in Phase 3); INCY RA drug doesn't have as many safety questions at this point I don't think. Anyways, market perceptions can change; I'd rather buy when the perceptions are low and hope for a rebound in sentiment as opposed to vice versa.